Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00084149 |
|
Recruitment Status :
Completed
First Posted : June 8, 2004
Results First Posted : September 13, 2018
Last Update Posted : September 13, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Cyclosporine A (CsA) is a common long-term treatment used to inhibit the immune response in transplant patients who receive donor organs. CsA may also help people with HIV. The purpose of this study is to determine the safety of and immune response to CsA when given with abacavir sulfate (ABC), lamivudine (3TC), and zidovudine (AZT), (ABC/3TC/AZT) and lopinavir/ritonavir (LPV/r) to HIV infected adults in the early stages of infection.
Study hypothesis: The combination of CsA and LPV/r given to acutely infected individuals will result in lower levels of proviral DNA and latent infectious virus at 48 weeks compared to acute infected individuals treated with LPV/r alone.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HIV Infections | Drug: Abacavir sulfate, Lamivudine, and Zidovudine Drug: Lopinavir/Ritonavir | Phase 2 |
During the early stages of HIV infection, HIV replicates unchecked, massive numbers of cluster of differentiation 4 (CD4) T cells are infected and destroyed, and other CD4 cells become infected but enter a latent phase. This latent pool of infected CD4 cells poses a difficult challenge in eliminating HIV infection during the early stages of infection because the cells persist for long periods, even with highly active effective antiretroviral therapy, and may later become active.
CsA is popularly used as a lifelong immunosuppressant for organ transplant patients. CsA inhibits cellular activation, including CD4 cell activation and proliferation. By reducing CD4 cell activation during acute HIV infection, fewer CD4 cells may be infected and die; more importantly, there may be fewer latent cells with the potential to become active later in the disease. However, CsA has many potential toxic effects, including renal damage, and may affect neurologic, endocrine, and hepatic organ systems.
In a previous small study of adults with acute HIV infection, a short 8-week course of CsA was well tolerated, and it is thought that a 4-week course of CsA may result in substantial reduction in both viral load and T cell activation, outweighing any potential toxic effects sustained during the one month treatment. This study will evaluate the safety of and immune response to a 4-week course of CsA with ABC/3TC/AZT and LPV/r compared to ABC/3TC/AZT and LPV/r alone in patients with acute HIV infection.
This 48-week study will randomly assign patients to one of two arms. During the first 4 weeks of the study, Arm A will receive one tablet of ABC/3TC/AZT twice daily, 3 capsules or 2 tablets of LPV/r twice daily, and liquid CsA (dose determined by weight) twice daily. At Week 5, Arm A patients will stop CsA but continue both ABC/3TC/AZT and LPV/r. Arm B will receive one tablet of ABC/3TC/AZT twice daily and 3 capsules or 2 tablets of LPV/r twice daily for all 48 weeks. On a case-by-case basis, an investigator may wish to prescribe ABC/3TC rather than ABC/3TC/AZT at initial therapy. Participants with ABC hypersensitivity will be given 3TC/AZT instead of ABC/3TC/AZT.
A complete physical exam and medical history assessment will occur at study entry and at Week 48. Study visits will occur every week until Week 4, then every 4 weeks until the end of the study. Blood and urine collection and clinical assessments will occur at each study visit. Additionally, patients in Arm A only will undergo CsA level monitoring at Day 3 and Weeks 1, 2, and 3; CsA dosage may be adjusted as necessary.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 54 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized Phase II Study of the Safety, Immunologic, and Virologic Effects of Cyclosporine A in Conjunction With Trizivir(R) and Kaletra(R) Versus Trizivir(R) and Kaletra(R) Alone During Primary HIV-1 Infection |
| Study Start Date : | February 2004 |
| Actual Primary Completion Date : | January 2008 |
| Actual Study Completion Date : | January 2008 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cyclosporin
Cyclosporin arm (Arm A) will receive one tablet of Abacavir sulfate, Lamivudine, and Zidovudine (ABC/3TC/AZT) twice daily, 3 capsules or 2 tablets of lopinavir/ritonavir (LPV/r) twice daily, and liquid cyclosporin A (CsA) (dose determined by weight) twice daily. At Week 5, Arm A patients will stop CsA but continue both ABC/3TC/AZT and LPV/r.
|
Drug: Abacavir sulfate, Lamivudine, and Zidovudine
antiretroviral therapy
Other Name: Trizivir Drug: Lopinavir/Ritonavir antiretroviral therapy
Other Name: Kaletra |
|
Experimental: No Cyclosporin
The No Cyclosporin arm (Arm B) will receive one tablet of Abacavir sulfate, Lamivudine, and Zidovudine (ABC/3TC/AZT) twice daily and 3 capsules or 2 tablets of lopinavir/ritonavir (LPV/r) twice daily for all 48 weeks
|
Drug: Abacavir sulfate, Lamivudine, and Zidovudine
antiretroviral therapy
Other Name: Trizivir Drug: Lopinavir/Ritonavir antiretroviral therapy
Other Name: Kaletra |
- Levels of Proviral DNA in Peripheral Blood Mononuclear Cells (PBMC) (log10) [ Time Frame: At 48 weeks after the start of treatment ]
- Adverse Events Related to Study Medication [ Time Frame: Up to 48 weeks ]Grade 1-4 adverse events related to study medication
- Proviral DNA Levels (log10) [ Time Frame: At Week 24 ]
- Proviral DNA (log10) [ Time Frame: At Week 12 ]
- HIV-1 Viral Load Levels [ Time Frame: At Week 48 ]
- Number of Patients With Viral Load Less Than 50 Copies/ml [ Time Frame: Week 48 ]
- CD4 T Cell Levels [ Time Frame: At Week 48 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Acute HIV infection with HIV viral load of more than 50,000 copies/ml AND either negative ELISA OR Western blot with 5 bands or less within 4 weeks prior to study entry
- Hepatitis B surface antigen negative within 12 weeks prior to study entry
- Hepatitis C antibody negative within 12 weeks prior to study entry
- Willing to use acceptable methods of contraception
Exclusion Criteria:
- Prior antiretroviral therapy. A patient who has undergone Post Exposure Prophylaxis (PEP) taken at least 6 months prior to study entry is not excluded.
- Allergy or hypersensitivity to any study medications or their components
- Require certain medications, including those that may alter CsA levels or cause renal dysfunction. More information on this criterion can be found in the protocol.
- Any medical or psychiatric condition, including alcohol or drug abuse, that may interfere with adherence to study requirements
- Weight less than 88 lbs (40 kg)
- Uncontrolled hypertension
- History of pancreatitis
- History of cancer. Participants with cancer in remission who have not had treatment for at least 3 years may be eligible for this study.
- Pregnancy or breastfeeding
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00084149
| United States, Minnesota | |
| University of Minnesota, ACTU | |
| Minneapolis, Minnesota, United States, 55455-0392 | |
| United States, New York | |
| Beth Israel Med. Ctr., ACTU | |
| New York, New York, United States, 10003 | |
| NY Univ. HIV/AIDS CRS | |
| New York, New York, United States, 10016-6481 | |
| United States, Ohio | |
| MetroHealth CRS | |
| Cleveland, Ohio, United States, 44109-1998 | |
| Study Chair: | Martin Markowitz, MD | Aaron Diamond AIDS Research Center | |
| Study Chair: | Susan Little, MD | Department of Medicine, University of California at San Diego |
Additional Information:
Publications:
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00084149 History of Changes |
| Other Study ID Numbers: |
AIN501/A5216 10023 ( Registry Identifier: DAIDS ES ) |
| First Posted: | June 8, 2004 Key Record Dates |
| Results First Posted: | September 13, 2018 |
| Last Update Posted: | September 13, 2018 |
| Last Verified: | August 2018 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
Acute Infection Treatment Naive |
Additional relevant MeSH terms:
|
Infection HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Lopinavir Lamivudine Zidovudine Abacavir |
Cyclosporine Dideoxynucleosides Cyclosporins HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors |